BiVictriX Therapeutics Plc (LON:BVX – Get Free Report) was up 17.6% during mid-day trading on Friday . The company traded as high as GBX 10 ($0.13) and last traded at GBX 10 ($0.13). Approximately 1,538,020 shares were traded during trading, an increase of 1,320% from the average daily volume of 108,326 shares. The stock had previously closed at GBX 8.50 ($0.11).
BiVictriX Therapeutics Price Performance
The company’s 50 day simple moving average is GBX 10 and its 200 day simple moving average is GBX 10.75. The company has a debt-to-equity ratio of 8.81, a current ratio of 4.40 and a quick ratio of 7.49. The stock has a market cap of £8.25 million, a P/E ratio of -250.00 and a beta of -0.73.
BiVictriX Therapeutics Company Profile
BiVictriX Therapeutics Plc, a biotechnology company, engages in the development of cancer therapies in the United Kingdom. The company develops Bi-Cygni therapeutics, which are selective for cancer types. Its lead program is BVX001, focuses on acute myeloid leukaemia, as well as develops BVX002 and BVX003 for various blood cancers and solid tumours.
Featured Articles
- Five stocks we like better than BiVictriX Therapeutics
- Why Invest in 5G? How to Invest in 5G Stocks
- What’s Behind These 3 Recent Analyst Stock Upgrades?
- How to Most Effectively Use the MarketBeat Earnings Screener
- Fast-Growing Companies That Are Still Undervalued
- How to Invest in the Best Canadian Stocks
- Top Cybersecurity Stock Picks for 2025
Receive News & Ratings for BiVictriX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiVictriX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
